Literature DB >> 21948302

Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein.

Mairead Looby1, Neysi Ibarra, James J Pierce, Kevin Buckley, Eimear O'Donovan, Mary Heenan, Enda Moran, Suzanne S Farid, Frank Baganz.   

Abstract

This study describes the application of quality by design (QbD) principles to the development and implementation of a major manufacturing process improvement for a commercially distributed therapeutic protein produced in Chinese hamster ovary cell culture. The intent of this article is to focus on QbD concepts, and provide guidance and understanding on how the various components combine together to deliver a robust process in keeping with the principles of QbD. A fed-batch production culture and a virus inactivation step are described as representative examples of upstream and downstream unit operations that were characterized. A systematic approach incorporating QbD principles was applied to both unit operations, involving risk assessment of potential process failure points, small-scale model qualification, design and execution of experiments, definition of operating parameter ranges and process validation acceptance criteria followed by manufacturing-scale implementation and process validation. Statistical experimental designs were applied to the execution of process characterization studies evaluating the impact of operating parameters on product quality attributes and process performance parameters. Data from process characterization experiments were used to define the proven acceptable range and classification of operating parameters for each unit operation. Analysis of variance and Monte Carlo simulation methods were used to assess the appropriateness of process design spaces. Successful implementation and validation of the process in the manufacturing facility and the subsequent manufacture of hundreds of batches of this therapeutic protein verifies the approaches taken as a suitable model for the development, scale-up and operation of any biopharmaceutical manufacturing process.
Copyright © 2011 American Institute of Chemical Engineers (AIChE).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21948302     DOI: 10.1002/btpr.672

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  3 in total

1.  Advanced multivariate data analysis to determine the root cause of trisulfide bond formation in a novel antibody-peptide fusion.

Authors:  Stephen Goldrick; William Holmes; Nicholas J Bond; Gareth Lewis; Marcel Kuiper; Richard Turner; Suzanne S Farid
Journal:  Biotechnol Bioeng       Date:  2017-06-05       Impact factor: 4.530

2.  Identification of growth phases and influencing factors in cultivations with AGE1.HN cells using set-based methods.

Authors:  Steffen Borchers; Susann Freund; Alexander Rath; Stefan Streif; Udo Reichl; Rolf Findeisen
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

3.  Unit operation optimization for the manufacturing of botanical injections using a design space approach: a case study of water precipitation.

Authors:  Xingchu Gong; Huali Chen; Teng Chen; Haibin Qu
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.